The Food and Drug Administration (FDA) has issued warning letters to Chewy and eight other manufacturers and distributors of antimicrobial animal drugs. The FDA claims that these medications are unapproved and misbranded, raising concerns about their potential impact on the development of antimicrobial resistance.
According to the FDA, the use of these products, which contain antimicrobials that are critical in human medicine, without proper medical oversight can contribute to the rise of antimicrobial resistance. The agency has not conducted a thorough evaluation of the safety or effectiveness of these products through its animal drug review process or facility inspections. Furthermore, the products are being illegally marketed over the counter.
The antimicrobial animal drugs in question are marketed and labeled for minor species such as aquarium fish and pet birds and include substances like amoxicillin and penicillin. However, their legality and adherence to regulatory standards are now being called into question.
Chewy and representatives from other companies, including Kraft Drug and California Veterinary Supply, have yet to respond to requests for comment on the matter.
As the FDA takes action to address potential risks associated with unapproved and misbranded antimicrobial animal drugs, it serves as a reminder of the importance of adhering to proper regulations and oversight to protect both animals and humans.
Our Latest News
Advance Auto Parts Inc. Faces Credit Downgrade
Advance Auto Parts Inc. experiences credit downgrade and struggles with execution issues, resulting in declining market share. Stock falls to lowest close in 12...
Germany and Nigeria Collaborate to Boost Power Supply
Germany and Nigeria have agreed to enhance the power sector in Nigeria through a collaborative project spearheaded by Siemens AG. The project aims to provide a...
Allergy Therapeutics Faces Challenges in Fiscal 2023
Allergy Therapeutics faced challenges in fiscal 2023 as its revenue declined, leading to an operating loss. The company's manufacturing capacity for clinical tr...